Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea.
Vaccine. 2013 Jul 11;31(32):3268-73. doi: 10.1016/j.vaccine.2013.05.023. Epub 2013 May 22.
In the present study, virus-like particles (VLPs) were evaluated as a candidate veterinary vaccine against canine influenza virus (CIV) subtype H3N2. Specific pathogen-free (SPF) beagle dogs received a single injection of a VLP vaccine containing hemagglutinin (HA) and M1 protein of CIV H3N2 (H3 HA VLP). The vaccine was tested at 3 different doses with an adjuvant and 1 dose without an adjuvant. To evaluate the immunogenicity and protective efficacy of the H3 HA VLP vaccine, we performed hemagglutination inhibition tests to determine serological immune responses and conducted challenge studies using SPF beagle dogs. The addition of Montanide ISA 25 adjuvant significantly increased the immunogenicity of the H3 HA VLP vaccine. The experimental infection study showed that a single dose of H3 HA VLP vaccine induced protection against wild-type virus challenge in dogs. These results provide support for continued development of the VLP as an animal vaccine against influenza virus.
在本研究中,病毒样颗粒 (VLPs) 被评估为一种针对犬流感病毒 (CIV) 亚型 H3N2 的候选兽用疫苗。特定无病原体 (SPF) 比格犬接受了单次注射含有血凝素 (HA) 和 CIV H3N2 M1 蛋白的 VLP 疫苗 (H3 HA VLP)。该疫苗在 3 种不同剂量下进行了测试,一种含有佐剂,一种不含有佐剂。为了评估 H3 HA VLP 疫苗的免疫原性和保护效力,我们进行了血凝抑制试验以确定血清学免疫反应,并使用 SPF 比格犬进行了攻毒研究。添加 Montanide ISA 25 佐剂显著提高了 H3 HA VLP 疫苗的免疫原性。实验感染研究表明,单次剂量的 H3 HA VLP 疫苗可诱导犬对野毒株的保护。这些结果为继续开发 VLP 作为流感病毒的动物疫苗提供了支持。